SCHEMBL1447166

SCHEMBL1447166

CC(=O)NCCOc1cc(F)cc(NC(=O)Nc2cccnc2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.54
CYP1A2 P05177 2/20 0.53
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
MAPT P10636 2/20 0.50
PKM P14618 1/20 0.50
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 2/20 0.47
NOTUM Q6P988 1/20 0.47
MEN1 O00255 3/20 0.46
LMNA P02545 3/20 0.46
KMT2A Q03164 3/20 0.46
CDK2 P24941 1/20 0.46
FLT4 P35916 1/20 0.46
EPHX2 P34913 1/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.45
TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1446022 0.91 TAAR1 (0.53) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446190 0.85 TAAR1 (0.51) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446136 0.84 TAAR1 (0.52) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446501 0.83 CYP1A2 (0.56) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1445986 0.83 CYP1A2 (0.49) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446014 0.82 CYP1A2 (0.54) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446227 0.82 TAAR1 (0.52) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL8350535 0.81 KDM4E (0.67) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1445958 0.80 CYP1A2 (0.50) TAAR1CYP1A2NPC1RAB9AMAPT
SCHEMBL1446011 0.79 CYP1A2 (0.56) TAAR1CYP1A2NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910743-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-03-22 US claimed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 US claimed
US-7910743-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2011-03-22 US disclosed
US-20090324511-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-12-31 US disclosed
US-7538223-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2009-05-26 US disclosed
US-20070066626-A1 Compounds, compositions and methods CYTOKINETICS, INCORPORATED 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324511-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 TAAR1 4657/4885CYP1A2 4662/4885NPC1 4608/4885
US-20070066626-A1 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 TAAR1 4657/4885CYP1A2 4662/4885NPC1 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.